胃旁路术对2型糖尿病患者的三年疗效分析

doi:10.3877/cma.j.issn.1674-6899.2018.05.003

目的

探讨腹腔镜胃旁路术(laparoscopic gastric bypass, LGBP)对中国2型糖尿病(type 2 diabetes mellitus, T2DM)患者术后3年的疗效及安全性。

方法

回顾性分析2012年4月至2014年3月在首都医科大学附属北京天坛医院接受LGBP治疗的58例T2DM患者的临床资料，观察术后3、6、9、12、24、36个月患者的体质量、血糖、血脂等指标，以及手术相关并发症，并用t检验或秩和检验比较手术前后相关指标的变化。

结果

58例T2DM患者全部完成LGBP，无中转开腹患者。患者的术后9个月体质量达到最低，术后12、24、36个月平均体质量均较术前明显减低，差异有统计学意义(P<0.05)。术后12、24、36个月T2DM完全缓解率分别为72.5%、71.4%、52.9%。空腹血糖(fasting plasmaglucose，FPG)在术后6个月降至最低；糖化血红蛋白(hemoglobin A1c, HbA1c)在术后9个月降至最低。术后12、24、36个月FPG和HbA1c均较术前明显降低，差异均有统计学意义(P< 0.05)。术后3年的三酰甘油、高密度脂蛋白及低密度脂蛋白也较术前明显改善，差异均有统计学意义(P< 0.05)。术后出现胃肠吻合口狭窄1例，小肠Y吻合口出血1例。

结论

LGBP对于中国T2DM患者中远期疗效仍是安全、有效的。

关键词: 腹腔镜, 胃旁路术, 2型, 　糖尿病, 减重手术

Objective

To investigate the curative effect of laparoscopic gastric bypass (LGBP) on type 2 diabetes mellitus(T2DM) for 3 years in China.

Methods

Clinical data of 58 patients with T2DM undergoing LGBP from Apr.2012 to Mar. 2014 was studied retrospectively. Weight, blood glucose, blood lipids and surgical complications were observed in 3, 6, 9, 12, 24 and 36 months after operation, and compared by t-test or rank sum test.

Results

Among 58 cases of T2DM patients were successfully completed LGBP without conversion to laparotomy. Weight reached the lowest level at 9 months after LGBP. The average weight were lower respectively at 12, 24 and 36 months postoperatively compared with preoperative (P< 0.05). The complete remission rate of T2DM were 72.5%, 71.4% and 52.9% respectively at 12, 24 and 36 months after operation. Fasting plasma glucose(FPG)decreased to a minimum level at 6 months after operation. Hemoglobin A1c (HbA1c) fell to a minimum level 9 months postoperatively. FPG and HbA1c were lower respectively at 12, 24 and 36 months postoperatively compared with preoperative (P< 0.05). Triglycerides, high density lipoprotein and low density lipoprotein were significantly improved three years after LGBP compared with preoperative (P< 0.05). There were 1 case of gastrointestinal anastomotic stenosis and 1 case of Y anastomotic bleeding in small intestine after LGBP.

Conclusions

LGBP is safe and effective in the mid-term effect of T2DM in China.

Key words: Laparoscopic, Gastric bypass, Type 2, Diabetes mellitus, Bariatric surgery

表1 腹腔镜胃旁路手术前后糖代谢指标的比较

时间	例数	FPG(mmol/L， ±s)	HbAlc(%, ±s)	HbA1c≤6.5%[例(%)]
术前	58	7.73±2.63	8.5±1.7	－
术后3个月	48	6.58±1.40^a	6.3±1.0^a	－
术后6个月	45	6.12±1.11^a	6.2±1.0^a	－
术后9个月	41	6.41±1.42^a	6.0±1.5^a	－
术后12个月	40	6.42±2.11^a	6.1±1.1^a	29(72.5)^b
术后24个月	35	6.49±1.49^a	6.3±1.1^a	25(71.4) ^b
术后36个月	34	6.91±1.53^a	6.7±1.2^a	18(52.9)^b

表1 腹腔镜胃旁路手术前后糖代谢指标的比较

时间	例数	FPG(mmol/L， ±s)	HbAlc(%, ±s)	HbA1c≤6.5%[例(%)]
术前	58	7.73±2.63	8.5±1.7	－
术后3个月	48	6.58±1.40^a	6.3±1.0^a	－
术后6个月	45	6.12±1.11^a	6.2±1.0^a	－
术后9个月	41	6.41±1.42^a	6.0±1.5^a	－
术后12个月	40	6.42±2.11^a	6.1±1.1^a	29(72.5)^b
术后24个月	35	6.49±1.49^a	6.3±1.1^a	25(71.4) ^b
术后36个月	34	6.91±1.53^a	6.7±1.2^a	18(52.9)^b

表2 腹腔镜胃旁路手术前后降血糖药物使用比较[例(%)]

时间	例数	未使用药物	使用药物			P值
时间	例数	未使用药物	口服降血糖药	胰岛素	口服降血糖药＋胰岛素	P值
术前	58	－	33(56.9)	11(19.0)	14(24.0)	－
术后12个月	56	39(69.6)	5(8.9)	12(21.4)	0(0.0)	< 0.001
术后24个月	52	41(78.8)	5(9.6)	4(7.7)	2(3.8)	< 0.001
术后36个月	40	30(75.0)	5(12.5)	4(10.0)	1(2.5)	< 0.001

表2 腹腔镜胃旁路手术前后降血糖药物使用比较[例(%)]

时间	例数	未使用药物	使用药物			P值
时间	例数	未使用药物	口服降血糖药	胰岛素	口服降血糖药＋胰岛素	P值
术前	58	－	33(56.9)	11(19.0)	14(24.0)	－
术后12个月	56	39(69.6)	5(8.9)	12(21.4)	0(0.0)	< 0.001
术后24个月	52	41(78.8)	5(9.6)	4(7.7)	2(3.8)	< 0.001
术后36个月	40	30(75.0)	5(12.5)	4(10.0)	1(2.5)	< 0.001

表3 腹腔镜胃旁路手术前后血脂的比较(mmol/L， ±s)

时间	例数	TG	TCHO	HDL	LDL
术前	58	2.30±2.11	4.79±0.92	1.14±0.23	2.76±0.77
术后3个月	46	1.24±0.68^a	4.38±0.80^a	1.25±0.31^a	2.59±0.62^a
术后6个月	43	1.09±0.61^a	4.15±0.68^a	1.47±0.62^a	2.25±0.57^a
术后9个月	39	1.37±0.82^a	4.35±0.81^a	1.43±0.62^a	2.48±0.69^a
术后12个月	40	1.07±0.54^a	4.25±0.80^a	1.43±0.33^a	2.39±0.65^a
术后24个月	34	1.23±0.90^a	4.47±0.79	1.47±0.32^a	2.60±0.68
术后36个月	28	1.22±0.68^a	4.57±0.91	1.47±0.42^a	2.71±0.88^a

表3 腹腔镜胃旁路手术前后血脂的比较(mmol/L， ±s)

时间	例数	TG	TCHO	HDL	LDL
术前	58	2.30±2.11	4.79±0.92	1.14±0.23	2.76±0.77
术后3个月	46	1.24±0.68^a	4.38±0.80^a	1.25±0.31^a	2.59±0.62^a
术后6个月	43	1.09±0.61^a	4.15±0.68^a	1.47±0.62^a	2.25±0.57^a
术后9个月	39	1.37±0.82^a	4.35±0.81^a	1.43±0.62^a	2.48±0.69^a
术后12个月	40	1.07±0.54^a	4.25±0.80^a	1.43±0.33^a	2.39±0.65^a
术后24个月	34	1.23±0.90^a	4.47±0.79	1.47±0.32^a	2.60±0.68
术后36个月	28	1.22±0.68^a	4.57±0.91	1.47±0.42^a	2.71±0.88^a

1	Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes[J]. New England Journal of Medicine, 2017, 376(7):641-641.
2	Cummings DE, Arterburn DE, Westbrook EO, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial[J]. Diabetologia, 2016, 59(5):945-953.
3	Ikramuddin S, Billington CJ, Lee WJ, et al. Roux-en-Y gastric bypass for diabetes (the diabetes surgery study): 2-year outcomes of a 5-year, randomised, controlled trial[J]. Lancet Diabetes & Endocrinology, 2015, 3(6):413-422.
4	Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery for diabetes: the international diabetes federation takes a position[J]. Journal of Diabetes, 2011, 3(4):261-264.
5	Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations[J]. Obesity Surgery, 2016, 39(11):1-20.
6	杨景哥，王存川，胡友主，等. 腹腔镜Roux-en-Y胃旁路手术治疗肥胖症和2型糖尿病[J]. 中华胃肠外科杂志，2010, 13(8):594-597.
7	白日星，李有国，秦超，等. 腹腔镜胃旁路手术治疗2型糖尿病的疗效[J]. 中华普通外科杂志，2015, 30(12):957-960.
8	闫文貌，白日星，徐天磊，等. 胃小弯空肠侧侧吻合在腹腔镜胃旁路术中的应用[J/CD]. 中华腔镜外科杂志(电子版), 2015, 8(3):14-18.
9	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版)[J]. 中国糖尿病杂志，2014, 30(8):893-942.
10	中国医师协会外科医师分会肥胖和糖尿病外科医师委员会. 中国肥胖和2型糖尿病外科治疗指南(2014)[J]. 中国实用外科杂志，2014, 8(11):1005-1010.
11	Mingrone G, Panunzi S, De GA, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial[J]. Lancet, 2015, 386(9997):964-973.
12	Lee WJ, Chong K, Chen JC, et al. Predictors of diabetes remission after bariatric surgery in asia[J]. Asian Journal of Surgery, 2012, 35(2):67-73.
13	Bhasker AG, Remedios C, Batra P, et al. Predictors of remission of T2DM and metabolic effects after laparoscopic Roux-en-Y gastric bypass in obese indian diabetics-a 5-year study[J]. Obesity Surgery, 2015, 25(7):1191-1197.
14	Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis[J]. American Journal of Medicine, 2009, 122(3):248-256.
15	Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes[J]. N Engl J Med, 2012, 366(17):1567-1576.
16	Courcoulas AP, Belle SH, Neiberg RH, et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial[J]. Jama Surgery, 2015, 150(10):931-931.
17	Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years[J]. Jama, 2012, 308(11):1122-1131.
18	Lakdawala M, Shaikh S, Bandukwala S, et al. Roux-en-Y, gastric bypass stands the test of time: 5-year results in low body mass index (30-35 kg/m ²) Indian patients with type 2 diabetes mellitus[J]. Surgery for Obesity & Related Diseases, 2013, 9(3):370-378.
19	Digiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up[J]. Surgery for Obesity & Related Diseases, 2010, 6(3):249-253.
20	Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes[J]. N Engl J Med, 2012, 212(9):1577-1585.
21	Yan Y, Sha Y, Yao G, et al. Roux-en-Y gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients：a systematic review and meta-analysis of randomized controlled trials[J]. Medicine, 2016, 95(17):3462-3462.
22	Courcoulas AP, Goodpaster BH, Eagleton JK, et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial[J]. Jama Surgery, 2014, 149(7):707-707.
23	Nguyen NT, Longoria M, Chalifoux S, et al. Gastrointestinal hemorrhage after laparoscopic gastric bypass[J]. Obesity Surgery, 2004, 14(10):1308-1312.
24	Mehran A, Szomstein S, Zundel N, et al. Management of acute bleeding after laparoscopic Roux-en-Y gastric bypass[J]. Obesity Surgery, 2003, 13(6):842-847.
25	Carrodeguas L, Szomstein S, Zundel N, et al. Gastrojejunal anastomotic strictures following laparoscopic Roux-en-Y gastric bypass surgery: analysis of 1291 patients[J]. Surgery for Obesity & Related Diseases, 2006, 2(2):92-97.
26	Peifer KJ, Shiels AJ, Azar R, et al. Successful endoscopic management of gastrojejunal anastomotic strictures after Roux-en-Y gastric bypass[J]. Gastrointestinal Endoscopy, 2007, 66(2):248-252.
27	Bai RX, Yan WM, Li YG, et al. Application of side-to-side anastomosis of the lesser curvature of stomach and jejunum in gastric bypass[J]. World Journal of Gastroenterology, 2016, 22(37):8398-8405.
28	Giordano S, Salminen P, Biancari F, et al. Linear stapler technique may be safer than circular in gastrojejunal anastomosis for laparoscopic Roux-en-Y gastric bypass: a meta-analysis of comparative studies[J]. Obesity Surgery, 2011, 21(12):1958-1964.
29	Schauer PR, Nor HZ, Rubino F. Metabolic surgery for treating type 2 diabetes mellitus: now supported by the world's leading diabetes organizations[J]. Cleveland Clinic Journal of Medicine, 2017, 84(7):47-47.
30	Nougou A, Suter M. Almost routine prophylactic cholecystectomy during laparoscopic gastric bypass is safe[J]. Obesity Surgery, 2008, 18(5):535-539.
31	Everhart JE. Contributions of obesity and weight loss to gallstone disease[J]. Annals of Internal Medicine, 1993, 119(10):1029-1035.
32	Fobi M, Lee H, Igwe D, et al. Prophylactic cholecystectomy with gastric bypass operation: incidence of gallbladder disease[J]. Obesity Surgery, 2002, 12(3):350-353.
33	Hamad GG, Ikramuddin S, Gourash WF, et al. Elective cholecystectomy during laparoscopic Roux-en-Y gastric bypass: is it worth the wait[J]. Obesity Surgery, 2003, 13(1):76-81.
34	Ellner SJ, Myers TT, Piorkowski JR, et al. Routine cholecystectomy is not mandatory during morbid obesity surgery[J]. Surgery for Obesity & Related Diseases, 2007, 3(4):456-460.
35	Portenier DD, Grant JP, Blackwood HS, et al. Expectant management of the asymptomatic gallbladder at Roux-en-gastric bypass[J]. Surgery for Obesity & Related Diseases, 2007, 3(4):476-479.

[1]	吴丰信, 吴英光, 俞建雄, 王胜. 腹腔镜辅助保留幽门胃部分切除术治疗早期胃中部癌近期疗效分析[J]. 中华普通外科学文献(电子版), 2021, 15(05): 326-330.
[2]	周仕海, 陈宏, 张静, 雒洪志, 冯春在, 孙浩, 钟思全. 结直肠肿瘤经自然腔道取出标本手术67例分析[J]. 中华普通外科学文献(电子版), 2021, 15(05): 340-343.
[3]	殷涛. 腹腔镜胰十二指肠切除术[J]. 中华普通外科学文献(电子版), 2021, 15(04): 0-.
[4]	蓝伟锋, 陈志坚, 洪汉崟, 陈剑伟, 黄兴华, 池小斌, 陈永标. 吲哚菁绿在腹腔镜肝切除中的应用[J]. 中华普通外科学文献(电子版), 2021, 15(04): 309-312.
[5]	陈松, 唐宇哲, 付猛, 苏博兴, 刘宇保, 肖博, 胡卫国, 李建兴. 良性输尿管狭窄的治疗：90例单中心回顾分析[J]. 中华腔镜泌尿外科杂志(电子版), 2021, 15(04): 313-316.
[6]	术者：张树彬助手：邢中强段佳悦李昂指导老师：刘建华剪辑：徐晨. 健侧先行原位右半肝+全尾状叶切除的腹腔镜肝门部胆管癌根治术[J]. 中华肝脏外科手术学电子杂志, 2021, 10(06): 0-.
[7]	褚薛慧. 腹腔镜肝右后叶切除术[J]. 中华肝脏外科手术学电子杂志, 2021, 10(06): 0-.
[8]	卢攀刘心怡李坚陈龙张伟. 经脐单孔腹腔镜左半肝切除术[J]. 中华肝脏外科手术学电子杂志, 2021, 10(06): 0-.
[9]	张硕, 杨军, 顾元龙. 腹腔镜胆囊切除术致胆道损伤的危险因素及处理[J]. 中华肝脏外科手术学电子杂志, 2021, 10(05): 470-473.
[10]	吴志明, 黄洪军, 孟兴成, 葛佳皓, 沈丽青, 胡常恩, 虞洪. ERAS理念在腹腔镜胆总管切开取石一期缝合术中的应用[J]. 中华肝脏外科手术学电子杂志, 2021, 10(05): 474-478.
[11]	丁天龙, 谷保红, 李雪梅, 胡继科, 张凡, 冯泽东, 马斌, 王琛, 陈昊. "脱衣法"腹腔镜胆囊切除术的应用[J]. 中华肝脏外科手术学电子杂志, 2021, 10(05): 498-501.
[12]	王峰杰, 陈焕伟, 刘颖, 雷秋成, 宁燕文. 腹腔镜胰体尾切除手术入路及安全性[J]. 中华肝脏外科手术学电子杂志, 2021, 10(05): 506-509.
[13]	李国林, 王秀, 陈桂婵, 邱逸红. 腹腔镜胰十二指肠切除术围手术期标准化管理[J]. 中华肝脏外科手术学电子杂志, 2021, 10(05): 510-513.
[14]	李涛, 吐尔洪江·吐逊, 沙地克·阿帕尔, 白磊, 曹峻, 何翼彪, 王智鹏, 赵晋明. 全腹腔镜活体供肝右半肝切取术一例并文献复习[J]. 中华肝脏外科手术学电子杂志, 2021, 10(05): 514-518.
[15]	蓝炘, 朴成林, 安峰铎, 谈明坤, 司振铎, 吴蔚, 赵娜, 冷建军. 3D腹腔镜与2D腹腔镜下肝癌切除术的短期疗效比较[J]. 中华临床医师杂志(电子版), 2021, 15(05): 327-330.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of 3-year effect of gastric bypass on type 2 diabetes mellitus

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Analysis of 3-year effect of gastric bypass on type 2 diabetes mellitus